These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 11743284

  • 1. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
    Egawa S, Suyama K, Matsumoto K, Kuwao S, Baba S.
    J Urol; 2002 Jan; 167(1):97-102. PubMed ID: 11743284
    [Abstract] [Full Text] [Related]

  • 2. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M.
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [Abstract] [Full Text] [Related]

  • 3. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 4. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H, Akakura K, Igarashi T, Ueda T, Ito H, Watanabe M, Nomura F, Ochiai T, Shimada H.
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [Abstract] [Full Text] [Related]

  • 5. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
    Presti JC, Hovey R, Carroll PR, Shinohara K.
    J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
    [Abstract] [Full Text] [Related]

  • 6. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B, Alkibay T, Tuncel A, Bozkirli I.
    Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
    [Abstract] [Full Text] [Related]

  • 7. The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
    Yamanaka K, Yamada Y, Kobayashi Y, Ueno K, Takechi Y, Hasegawa E, Chikahira Y.
    Hinyokika Kiyo; 2003 Jan; 49(1):5-10. PubMed ID: 12629773
    [Abstract] [Full Text] [Related]

  • 8. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J, Raventós CX, Lorente JA, Lopez-Pacios MA, Encabo G, de Torres I, Andreu J.
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [Abstract] [Full Text] [Related]

  • 9. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
    Sözen S, Eskicorapci S, Küpeli B, Irkilata L, Altinel M, Ozer G, Uygur C, Alkibay T, Ozen H.
    Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190
    [Abstract] [Full Text] [Related]

  • 10. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J, Haese A, Scattoni V, Steuber T, Chun FK, Briganti A, Montorsi F, Graefen M, Huland H, Karakiewicz PI.
    Cancer; 2008 Nov 15; 113(10):2695-703. PubMed ID: 18853417
    [Abstract] [Full Text] [Related]

  • 11. Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study.
    Gjengstø P, Paus E, Halvorsen OJ, Eide J, Akslen LA, Wentzel-Larsen T, Hoisaeter PA.
    J Urol; 2005 Feb 15; 173(2):425-8. PubMed ID: 15643193
    [Abstract] [Full Text] [Related]

  • 12. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, Babaian R, Childs SJ, Stamey T, Fritsche HA, Sokoll L, Chan DW, Thiel RP, Cheli CD.
    J Urol; 2003 Nov 15; 170(5):1787-91. PubMed ID: 14532777
    [Abstract] [Full Text] [Related]

  • 13. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
    Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schröder FH.
    J Urol; 1997 Jun 15; 157(6):2191-6. PubMed ID: 9146612
    [Abstract] [Full Text] [Related]

  • 14. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
    Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, Bruzek DJ, Morris DL, Sokoll LJ, Chan DW, Yeung KK, Partin AW, Allard WJ.
    J Urol; 2000 May 15; 163(5):1476-80. PubMed ID: 10751861
    [Abstract] [Full Text] [Related]

  • 15. Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer.
    Haroun AA, Hadidy AS, Awwad ZM, Nimri CF, Mahafza WS, Tarawneh ES.
    Saudi J Kidney Dis Transpl; 2011 Mar 15; 22(2):291-7. PubMed ID: 21422628
    [Abstract] [Full Text] [Related]

  • 16. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y, Okamura K, Takamura S, Okamoto N, Narishima M, Yoshino Y, Hattori R, Ono Y, Ohshima S, Nagasaka T.
    Int J Urol; 2005 Aug 15; 12(8):721-7. PubMed ID: 16174045
    [Abstract] [Full Text] [Related]

  • 17. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer.
    Mitchell ID, Croal BL, Dickie A, Cohen NP, Ross I.
    J Urol; 2001 May 15; 165(5):1549-53. PubMed ID: 11342915
    [Abstract] [Full Text] [Related]

  • 18. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels.
    Cookson MS, Floyd MK, Ball TP, Miller EK, Sarosdy MF.
    J Urol; 1995 Sep 15; 154(3):1070-3. PubMed ID: 7543601
    [Abstract] [Full Text] [Related]

  • 19. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T, Kawahara T, Nishizawa K, Ogura K, Mitsumori K, Ide Y.
    BJU Int; 2005 Jun 15; 95(9):1245-8. PubMed ID: 15892809
    [Abstract] [Full Text] [Related]

  • 20. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
    Zlotta AR, Remzi M, Snow PB, Schulman CC, Marberger M, Djavan B.
    J Urol; 2003 May 15; 169(5):1724-8. PubMed ID: 12686818
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.